Expression analysis of δ‐catenin and prostate‐specific membrane antigen: Their potential as diagnostic markers for prostate cancer
暂无分享,去创建一个
H. Samaratunga | J. Clements | R. Gardiner | Patricia A. Keith | Judith Clements | Michelle Jane Burger | Michelle Anne Tebay | Patricia Anne Keith | Hema Mali Samaratunga | Martin Francis Lavin | Robert Alexander Gardiner | M. Burger | M.F. Lavin | Michelle Anne Tebay | Michelle A. Tebay | M. F. Lavin | M. Lavin
[1] T. Stamey,et al. Zonal Distribution of Prostatic Adenocarcinoma: Correlation with Histologic Pattern and Direction of Spread , 1988, The American journal of surgical pathology.
[2] L. Tsai,et al. A family of human cdc2‐related protein kinases. , 1992, The EMBO journal.
[3] E. Sprinzak,et al. Prediction of gene function by genome-scale expression analysis: prostate cancer-associated genes. , 1999, Genome research.
[4] P. Schellhammer,et al. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. , 1995, Urologic oncology.
[5] J. Schalken,et al. Complex cadherin expression in human prostate cancer cells , 2000, International journal of cancer.
[6] J. Fletcher,et al. Expression of metallopanstimulin and oncogenesis in human prostatic carcinoma. , 1997, Anticancer research.
[7] A. Ullrich,et al. Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine kinase family. , 1995, Oncogene.
[8] M. Oberholzer,et al. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. , 1979, The Journal of urology.
[9] P. Pandolfi,et al. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse , 2001, Nature Genetics.
[10] M. Rubin,et al. Tissue microarray assessment of prostate cancer tumor proliferation in African- American and white men. , 2000, Journal of the National Cancer Institute.
[11] J. Schalken,et al. Cadherin switching in human prostate cancer progression. , 2000, Cancer research.
[12] Daniel S. Miller,et al. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. , 1999, Journal of the National Cancer Institute.
[13] M. Bittner,et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. , 2001, Cancer research.
[14] E. Maestrini,et al. A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[15] D. Rimm,et al. The expression of p120ctn protein in breast cancer is independent of alpha- and beta-catenin and E-cadherin. , 1998, The American journal of pathology.
[16] J. Nakayama,et al. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. , 1997, Cancer research.
[17] L. Martínez-Piñeiro,et al. Determination of the Percentage of Free Prostate–Specific Antigen Helps to Avoid Unnecessary Biopsies in Men with Normal Rectal Examinations and Total Prostate–Specific Antigen of 4–10 ng/ml , 2000, European Urology.
[18] C C Schulman,et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. , 2000, The Journal of urology.
[19] K. Kosik,et al. δ-catenin, an Adhesive Junction–associated Protein Which Promotes Cell Scattering , 1999, The Journal of cell biology.
[20] W. Fair,et al. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. , 1995, Cancer research.
[21] M. Loda,et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[22] Thomas D. Schmittgen,et al. Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. , 2000, Journal of biochemical and biophysical methods.
[23] J. Schalken,et al. Decreased expression of alpha-catenin is associated with poor prognosis of patients with localized renal cell carcinoma. , 1998, International Journal of Cancer.
[24] M. Lovett,et al. Presenilin 1 interaction in the brain with a novel member of the Armadillo family , 1997, Neuroreport.
[25] T. Ried,et al. Cell cycle-dependent expression of Nek2, a novel human protein kinase related to the NIMA mitotic regulator of Aspergillus nidulans. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[26] J. Schalken,et al. Decreased expression of α‐catenin is associated with poor prognosis of patients with localized renal cell carcinoma , 1997 .
[27] L. Liotta,et al. Identification of a novel transcript up-regulated in a clinically aggressive prostate carcinoma. , 1997, Urology.
[28] T. Nevalainen,et al. Group II phospholipase A2 in human male reproductive organs and genital tumors , 1998, The Prostate.
[29] R. Hubert,et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[30] W Pruzanski,et al. Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. , 1989, The Journal of biological chemistry.
[31] W. Isaacs,et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.
[32] Roger E Bumgarner,et al. Prostate short-chain dehydrogenase reductase 1 (PSDR1): a new member of the short-chain steroid dehydrogenase/reductase family highly expressed in normal and neoplastic prostate epithelium. , 2001, Cancer research.
[33] V. Reuter,et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] W. Fair,et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. , 1993, Cancer research.
[35] A W Partin,et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.
[36] W. Franke,et al. Identification and localization of a neurally expressed member of the plakoglobin/armadillo multigene family. , 1997, Differentiation; research in biological diversity.
[37] J. Clements,et al. Kallikrein gene family expression in the rat ovary: localization to the granulosa cell. , 1995, Endocrinology.
[38] P. Weijerman,et al. Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA. , 1994, Cancer research.
[39] M. Plebani,et al. Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when? , 2000, Urology.
[40] V. Reuter,et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.
[41] Siavash Ghaffari,et al. A candidate prostate cancer susceptibility gene at chromosome 17p , 2001, Nature Genetics.
[42] M. Loda,et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer , 2000, Oncogene.
[43] J. Welsh,et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.
[44] P. Schellhammer,et al. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. , 1997, Urology.
[45] S. Dhanasekaran,et al. Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.
[46] V. Sukhatme,et al. cDNA sequence of the human cellular early growth response gene Egr-1. , 1990, Nucleic acids research.
[47] J. Isaacs,et al. Prostate‐specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells , 2000, The Prostate.
[48] P. Kantoff,et al. Two differentially expressed genes in normal human prostate tissue and in carcinoma. , 1996, Cancer research.
[49] T. P. Ball,et al. The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels. , 1995, The Journal of urology.
[50] N. Konishi,et al. E-cadherin and α-, β- and γ-catenin expression in prostate cancers: correlation with tumour invasion , 1999, British Journal of Cancer.
[51] T C Gasser,et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. , 1999, Cancer research.